clinical trial · NCT03900377
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
Lymphoma, B-cell, DiffuseSyB L-0501RI
brief summary
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell lymphoma (MCL), and the safety and tolerability will be investigated in patients with recurrent/refractory diffuse large B-cell lymphoma (DLBCL).
started
Apr 1, 2019
primary completion
Sep 9, 2020
completion
Feb 26, 2021
last updated
Nov 24, 2023
official title
A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 Minutes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol